This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. It has been well-established that tumors can elicit an immune response and that strategies which target the immune response can result in tumor regression. However, the precise mechanisms for tumor recognition and destruction remain inadequately defined, and correlation of anti-tumor immunity in the lab with clinical reductions in tumor size has been difficult. Because of the longstanding interest at UCHC in tumor immunology, many patients have been treated on clinical trials with some type of immunotherapy or tumor vaccine. Detailed analysis of the ability of these patients to respond to tumors may contribute to better understanding of the immune response to cancer and to the development of more effective therapies. This protocol proposes to perform outpatient leukapheresis to increase the number of patient lymphocytes available for study. This will be performed on patients who have previously been treated on a tumor vaccine protocol at UCHC, and also on a small number of normal controls.
Showing the most recent 10 out of 638 publications
